Severe Acute Respiratory Syndrome (SARS) Infection Drug Pipeline Study, H2 2018- Analysis of Phases, Companies, Mechansim, Trials, Current Status of Pipeline Drugs for Severe Acute Respiratory Syndrome (SARS)

September 2018 | 65 pages | ID: SD3F27A0FCFEN
VPAResearch

Abstracts

Severe Acute Respiratory Syndrome (SARS) Infection Drug Development Pipeline Study, H2 2018 is the latest infectious disease publication with comprehensive information of Severe Acute Respiratory Syndrome (SARS) Infection pipeline products.

DISEASE OVERVIEW

Severe Acute Respiratory Syndrome (SARS) infection is spread through Clostridium tetani bacteria, which is present in the form of spores in the environment and develops as bacteria upon entering into human body. Painful muscle contractions are the primary symptom and the disease is also referred to as ‘lockjaw’ as jaw muscles are tightened in tetanus infected patient.

Different forms of tetanus include - general, local and cephalic tetanus. Sudden spasms of the vocal cords, fractures, infections, aspiration pneumonia are the major complications of the disease.

Despite low costs of treatment, tetanus is rapidly progressing infectious disease, causing mortality. Fourteen companies are currently developing vaccines and treatment options against tetanus infections. The companies in global tetanus pipeline include - Beijing Minhai Biotechnology Co Ltd, BIKEN Corporation, Biological E Ltd, Cadila Healthcare Ltd, Daiichi Sankyo Company, GC Pharma - Korea, GlaxoSmithKline Plc, Indian Immunologicals Ltd, LG Chem Ltd, Olymvax Biopharmaceuticals Inc, Panacea Biotec Ltd, Sanofi, Serum Institute of India Ltd and Wockhardt Ltd.

REPORT DESCRIPTION

The Severe Acute Respiratory Syndrome (SARS) Infection pipeline guide presents complete overview of drugs currently being developed for Severe Acute Respiratory Syndrome (SARS) Infection. The pipeline review provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials).

Drug development phase, current stage, mechanism of action, route of administration, orphan drug/ fast track/ other designations, drug class are provided for each of the Severe Acute Respiratory Syndrome (SARS) Infection pipeline candidate.

Research and Development progress along with latest news related to each of the Severe Acute Respiratory Syndrome (SARS) Infection pipeline candidates is included.

Major companies participating in therapeutic development of Severe Acute Respiratory Syndrome (SARS) Infection are included in this pipeline report. Company wise pre-clinical and clinical products along with details of drug originator, co-developers/ licensors are provided.

Amid strong interest for cure of Severe Acute Respiratory Syndrome (SARS) Infection from companies and institutes, the current research work serves as a reliable and comprehensive source of information of global Severe Acute Respiratory Syndrome (SARS) Infection clinical and pre-clinical products.

The report assists in identifying potential upcoming companies and drugs in Severe Acute Respiratory Syndrome (SARS) Infection pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.

Information in the report is sourced from our proprietary platform, built through extensive primary and secondary research methodology. Data is presented in user friendly and ready to use format.

SCOPE OF SEVERE ACUTE RESPIRATORY SYNDROME (SARS) INFECTION PIPELINE REPORT INCLUDES

• Panorama of Severe Acute Respiratory Syndrome (SARS) Infection pipeline markets including statistics on therapeutic drugs and companies involved
• Severe Acute Respiratory Syndrome (SARS) Infection Pipeline candidates across various development phases including both pre-clinical, discovery and clinical stages are covered
• Severe Acute Respiratory Syndrome (SARS) Infection pipeline candidates across various ‘Mechanism of Actions’ are also presented in the study
• Overview of companies participating in Severe Acute Respiratory Syndrome (SARS) Infection pipeline with short introduction to their businesses and pipeline projects
• For each pipeline candidate, drug overview, details of mechanism of Action (MOA), originator, co-developer and licensee are provided.
• Research and Development progress and trial details, results wherever available, are also included in the pipeline study
• The pipeline study provides information on all ongoing and active projects and also presents the recent news associated with Severe Acute Respiratory Syndrome (SARS) Infection pipeline therapeutics

REASONS TO BUY

• Get clear understanding of the entire Severe Acute Respiratory Syndrome (SARS) Infection pipeline, with details on active projects
• Get in detail information of each product with updated information on each project along with key milestones
• Know the list of companies participating in global Severe Acute Respiratory Syndrome (SARS) Infection pipeline along with progress of each of the company’s products and information on associations/collaborations/licensing data
• Get trial information for each pipeline product under development
• Understand the pipeline structure in terms of mechanism of Action, phase and company

Contents

I. KEY FINDINGS

1. Companies Investing in Severe Acute Respiratory Syndrome (SARS) Infection Pipeline include
  Number of Companies with Severe Acute Respiratory Syndrome (SARS) Infection projects in pre-clinical Development
  Number of Companies with Severe Acute Respiratory Syndrome (SARS) Infection projects in Clinical Development
  Severe Acute Respiratory Syndrome (SARS) Infection Pipeline Companies based in Americas
  Severe Acute Respiratory Syndrome (SARS) Infection Pipeline Companies based in Europe
  Severe Acute Respiratory Syndrome (SARS) Infection Pipeline Companies based in Asia Pacific
  Severe Acute Respiratory Syndrome (SARS) Infection Pipeline Companies based in Rest of the World
2. Pipeline Candidates include
  Severe Acute Respiratory Syndrome (SARS) Infection Pipeline Agents in Pre- clinical/Discovery stage of Development
  Severe Acute Respiratory Syndrome (SARS) Infection Pipeline Agents in Clinical Development stage
  Severe Acute Respiratory Syndrome (SARS) Infection Pipeline Therapeutic Compounds received special status
  Mechanism of Action of most pipeline Drugs
  Small molecules among the Severe Acute Respiratory Syndrome (SARS) Infection Pipeline agents

II. INSIGHTS INTO SEVERE ACUTE RESPIRATORY SYNDROME (SARS) INFECTION PIPELINE

1. Disease Overview
  Introduction to Severe Acute Respiratory Syndrome (SARS) Infection
  Symptoms and Causes of Severe Acute Respiratory Syndrome (SARS) Infection
  Treatment or Prevention Options for Severe Acute Respiratory Syndrome (SARS) Infection
  Other Details
2. Phase wise Pipeline Compounds
  Severe Acute Respiratory Syndrome (SARS) Infection Pipeline Pre- Clinical/Discovery stage Drugs
  Severe Acute Respiratory Syndrome (SARS) Infection Pipeline Phase 1 stage Drugs
  Severe Acute Respiratory Syndrome (SARS) Infection Pipeline Phase 2 stage Drugs
  Severe Acute Respiratory Syndrome (SARS) Infection Pipeline Phase 3 stage Drugs
  Severe Acute Respiratory Syndrome (SARS) Infection Pipeline Pre-Registration stage Drugs
3. Company wise Severe Acute Respiratory Syndrome (SARS) Infection Pipeline Compounds
4. Severe Acute Respiratory Syndrome (SARS) Infection Pipeline by Mechanism of Action

III. SEVERE ACUTE RESPIRATORY SYNDROME (SARS) INFECTION PIPELINE COMPOUND DETAILS

TVB-3567
Drug for MERS ans SERS
CSW-1
Small Molecule fo SARS (E protein)
CEL-1000
SARS vaccine
GS-5734
monoclonal antibody for SARS
SARS VLP vaccine
Poly-ICLC
Antivaral for SARS
D3252
Drug Details
  1. Snapshot
    Name of the Therapeutic Agent
     Originator
    Developing Company
    Co-Developer/License Partner
    Orphan Drug/Fast Track/Designation
    Development Phase
  2. Drug Overview
  3. Mechanism of Action
  4. Current Status
  5. Clinical Trial Details

IV. SEVERE ACUTE RESPIRATORY SYNDROME (SARS) INFECTION PIPELINE COMPANY BRIEFS

3-V Biosciences Inc
Abhelix LLC
Autoimmune Technologies LLC
Biotron Ltd
CEL-SCI Corp
GeneCure LLC
Gilead Sciences Inc
MassBiologics
Novavax Inc
Oncovir Inc
Phelix Therapeutics LLC
Sanofi

V. LATEST NEWS AND DEVELOPMENTS IN GLOBAL SEVERE ACUTE RESPIRATORY SYNDROME (SARS) INFECTION PIPELINE MARKET

VI. APPENDIX

1. Publisher’s Expertise
2. Research Methodology
3. Contact Information
Some of the sections depicted above may be removed or modified on the basis of information availability